Evidence map›Paper›PMID 30066932›Full record

ArticleMolecular medicine reports2018

Silencing Tspan1 inhibits migration and invasion, and induces the apoptosis of human pancreatic cancer cells.

Jiaxun Tian, Rui Zhang, Haiyan Piao, Xiaoxi Li, Weiwei Sheng, Jianping Zhou, Ming Dong, Xiaobo Zhang, Xiaofei Yan, Wen Shang and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Functional analysis ofThe Journal of general virology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. miR-573 suppresses pancreatic cancer cell proliferation, migration, and invasion through targeting TSPAN1.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Jiaxun TianDepartment of Laboratory, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Rui ZhangDepartment of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Haiyan PiaoDepartment of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Xiaoxi LiDepartment of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Weiwei ShengGastrointestinal Surgery Department, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Jianping ZhouGastrointestinal Surgery Department, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Ming DongGastrointestinal Surgery Department, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Xiaobo ZhangGeneral Surgery Department, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Xiaofei YanDepartment of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Wen ShangDepartment of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Jianfeng ZhaoDepartment of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Lan XuDepartment of Laboratory, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Fang LiuDepartment of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Gang ShiDepartment of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
China Medical University · CNLiaoning Cancer Hospital & Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PCC) is one of the most dangerous types of tumor as it is very difficult to treat and its 5‑year survival rate is <6%. To date, there have been no effective therapeutic strategies to treat PCC, thus, novel effective therapeutic methods are required. Tetraspanin 1 (Tspan1) is a novel member of the tetraspanins superfamily and is highly expressed in a variety of types of cancer, including gastric, hepatocellular and colonic carcinomas. However, the detailed functional role of Tspan1 in pancreatic cancer cells is still unclear and further investigation is required to uncover its therapeutic potential for the treatment of different tumor types. The purpose of the present study was to investigate the expression of Tspan1 in human PCC tissues and cells, and explore the effect of Tspan1 silencing on invasion, migration, cell survival and apoptosis in human PCC to clarify its function. Expression levels of Tspan1 were analyzed in human pancreatic cancer tissues and the cell lines Capan‑2 and SW1990 using immunohistochemistry staining, reverse transcription‑quantitative polymerase chain reaction and western blotting. The effects of downregulation of Tspan1 expression on cell survival, apoptosis, invasion and migration were investigated viaTspan1‑small interfering (si)RNA transfection into human PCC cell lines. The results indicated that Tspan1 expression was increased in human PCC tissues compared with the adjacent normal pancreatic tissues. Tspan1 was highly expressed in the human PCC cell lines Capan‑2 and SW1990 when compared with the normal pancreatic cell line HPC‑Y5. In addition, transfection with siRNA‑targeting Tspan1 significantly reduced cell migration and invasion, and increased the cell apoptosis of Capan‑2 and SW1990. The present findings highlighted the important role of Tspan1 in human PCC cell migration, invasion and apoptosis. Thus, Tspan1 RNA interference may serve as a potential therapeutic strategy to treat human PCC.

Indexed as

Gene SilencingApoptosisCell Line, TumorCell MovementGene ExpressionGene Knockout TechniquesHumansImmunohistochemistryPancreatic NeoplasmsRNA, Small InterferingTetraspaninsRNA, Small InterferingTetraspaninsTSPAN1 protein, human

Identifiers

PMID30066932
PMCPMC6102649
OpenAlexW2883350499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.